Durvalumab

Durvalumab[4] (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca.[5] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). Durvalumab is known as a checkpoint inhibitor drug.[6] Contents 1 Medical uses 2 Clinical trials 2.1 MYSTIC 2.2 PACIFIC 2.3 CASPIAN 3 References 4 External lin... [wikipedia]